PDF(Pubmed)
Abstract：
UNASSIGNED: Remdesivir (REM) and molnupiravir (MOL) are commonly used to treat lung transplant recipients (LTRs) with COVID-19; however, the clinical efficacy of these medications is yet to be compared. In this retrospective cohort study, we compared the clinical outcomes between LTRs with mild-to-moderate COVID-19 treated with REM and those treated with MOL.
UNASSIGNED: Between March 2020 and August 2022, 195 LTRs developed COVID-19 at our center. After excluding 82 who presented with severe disease requiring hospitalization, the remaining 113 were included in the analysis: 54 did not receive antiviral treatment, 30 were treated with REM, and 29 were treated with MOL. Adjusted multivariable logistic regression analysis showed similar rates of hospitalization (adjusted odds ratio (aOR) 1.169, [95% confidence interval (95% CI) 0.105-12.997, p = 0.899], ICU admission (aOR 0.822, 95% CI 0.042-16.220, p = 0.898), mechanical ventilation (aOR 0.903, 95% CI 0.015-55.124, p = 0.961), and COVID-19-related mortality (aOR 0.822, 95% CI 0.042-16.220, p = 0.898) between LTRs treated with REM and those treated with MOL for mild-to-moderate COVID-19, irrespective of SARS-CoV-2 strain.
UNASSIGNED: MOL may be a suitable alternative to REM to treat LTRs with mild-to-moderate COVID-19, and the choice of antiviral therapy can be driven by practical considerations such as route of administration and drug availability.
UNASSIGNED: Between March 2020 and August 2022, 195 LTRs developed COVID-19 at our center. After excluding 82 who presented with severe disease requiring hospitalization, the remaining 113 were included in the analysis: 54 did not receive antiviral treatment, 30 were treated with REM, and 29 were treated with MOL. Adjusted multivariable logistic regression analysis showed similar rates of hospitalization (adjusted odds ratio (aOR) 1.169, [95% confidence interval (95% CI) 0.105-12.997, p = 0.899], ICU admission (aOR 0.822, 95% CI 0.042-16.220, p = 0.898), mechanical ventilation (aOR 0.903, 95% CI 0.015-55.124, p = 0.961), and COVID-19-related mortality (aOR 0.822, 95% CI 0.042-16.220, p = 0.898) between LTRs treated with REM and those treated with MOL for mild-to-moderate COVID-19, irrespective of SARS-CoV-2 strain.
UNASSIGNED: MOL may be a suitable alternative to REM to treat LTRs with mild-to-moderate COVID-19, and the choice of antiviral therapy can be driven by practical considerations such as route of administration and drug availability.
摘要：
■Remdesivir(REM)和Molnupiravir(MOL)通常用于治疗COVID-19的肺移植受体(LTRs)；然而，这些药物的临床疗效尚待比较。在这项回顾性队列研究中，我们比较了接受REM和接受MOL治疗的轻度至中度COVID-19的LTR和轻度至中度COVID-19的临床结局.
■在2020年3月至2022年8月之间，有195个LTR在我们中心开发了COVID-19。在排除82名患有严重疾病需要住院治疗的患者后，其余113个被纳入分析:54个没有接受抗病毒治疗,30例接受REM治疗，29例接受MOL治疗。调整后的多变量逻辑回归分析显示住院率相似（调整后的比值比（aOR）1.169，[95％置信区间（95％CI）0.105-12.997，p=0.899]，ICU入院（aOR0.822，95%CI0.042-16.220，p=0.898），机械通气（aOR0.903，95%CI0.015-55.124，p=0.961），与COVID-19相关的死亡率(aOR0.822，95%CI0.042-16.220，p=0.898)在接受REM治疗和接受MOL治疗的轻度至中度COVID-19之间，与SARS-CoV-2株无关。
■MOL可能是REM治疗轻度至中度COVID-19的LTR的合适替代品，抗病毒治疗的选择可以由实际考虑因素驱动，例如给药途径和药物可用性。
■在2020年3月至2022年8月之间，有195个LTR在我们中心开发了COVID-19。在排除82名患有严重疾病需要住院治疗的患者后，其余113个被纳入分析:54个没有接受抗病毒治疗,30例接受REM治疗，29例接受MOL治疗。调整后的多变量逻辑回归分析显示住院率相似（调整后的比值比（aOR）1.169，[95％置信区间（95％CI）0.105-12.997，p=0.899]，ICU入院（aOR0.822，95%CI0.042-16.220，p=0.898），机械通气（aOR0.903，95%CI0.015-55.124，p=0.961），与COVID-19相关的死亡率(aOR0.822，95%CI0.042-16.220，p=0.898)在接受REM治疗和接受MOL治疗的轻度至中度COVID-19之间，与SARS-CoV-2株无关。
■MOL可能是REM治疗轻度至中度COVID-19的LTR的合适替代品，抗病毒治疗的选择可以由实际考虑因素驱动，例如给药途径和药物可用性。
